Eloralintide, Cagrilintide, Petrelintide and AZD6234 are each a copy of amylin.
Amylin is the fullness hormone your pancreas releases alongside insulin.
| Comparison | Eloralintide LY3841136 · Elora | Cagrilintide AM833 · EZP-CG | Petrelintide ZP8396 | AZD6234 lenbelintide |
|---|---|---|---|---|
| How it works | How it works Eloralintide is an amylin receptor agonist designed with tolerability as the main goal. | How it works Cagrilintide copies amylin rather than GLP-1. Amylin is a separate fullness hormone your pancreas releases alongside insulin, which is why it can be combined with a GLP-1 drug instead of competing with one. | How it works Petrelintide is a long-acting amylin copy positioned as a standalone weight-loss drug rather than an add-on to a GLP-1. | How it works AZD6234 is a long-acting amylin copy built for selectivity: it favours the amylin receptor over the calcitonin receptor. |
| What it is | An experimental weekly fullness-hormone shot for weight loss. | A weekly fullness-hormone shot, often paired with semaglutide for bigger loss. | An experimental weekly fullness-hormone shot for weight loss. | An experimental weekly fullness-hormone shot from AstraZeneca, tuned to the amylin receptor. |
| Status | In trialsInvestigational | In trialsInvestigational | In trialsInvestigational | In trialsInvestigational |
| Typical dose | 1–9 mg per week | 0.3–4.5 mg per dose | 0.6–9 mg per week | — |
| How often | Weekly | Weekly | Weekly | Weekly |
| Stays active | 14 to 16 days | About 8 days | About 10 days | Not established |
| Dose comes from | Clinical trial protocol | Clinical trial protocol | Clinical trial protocol | Clinical trial protocol |
| Cycled? | Not cycled in the trials Clinical trial protocol | Not cycled in the trials Clinical trial protocol | Not cycled in the trials Clinical trial protocol | Not cycled in the trials Clinical trial protocol |
| What it does | ||||
| Drug class | Amylin agonist | Amylin analog | Amylin analog | Amylin analog |
| Used for | An experimental weekly shot that copies a natural fullness hormone for weight loss, positioned as easy to tolerate. | People use it to feel full and eat less by copying a natural fullness hormone. It is often paired with semaglutide for bigger weight loss. | An experimental weekly shot that copies a natural fullness hormone to reduce appetite, positioned as a gentler standalone option. | An experimental weekly shot that copies a natural fullness hormone to reduce appetite, designed to prefer the amylin receptor over the calcitonin receptor. |
| Receptors hit | amylin | amylin | amylin | amylin |
| Numbers | ||||
| Full dose line | 1 up to 9 mg per week (trial doses) | 0.3 up to 4.5 mg per dose (start low, increase slowly) | 0.6 up to 9 mg per week (start low, increase slowly) | Once weekly in trials; milligram dose levels have not been publicly disclosed |
| Why that cycle | Given continuously for the whole study period: 48 weeks in phase 2, 75 to 80 weeks in phase 3. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break. | Given continuously for the whole study period: 26 weeks on its own, 68 weeks as part of REDEFINE 1. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break. | Given continuously for the whole study period: ZUPREME-1, 42 weeks. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break. | Given continuously for the whole study period, with the dose stepped up at the start, which is a ramp rather than a cycle. |
| Weight / effect | Not measured in a trial | Not measured in a trial | Not measured in a trial | Not measured in a trial |
| Chain length | 37 residues | 37 residues | 36 residues | 37 residues |
| Common vial | 10 mg | 10 mg | 10 mg | — |
| Before you start | ||||
| Route | Under the skin (subcutaneous) | Under the skin (subcutaneous) | Under the skin (subcutaneous) | Under the skin (subcutaneous) |
| Do not use if | No formal contraindications established Pregnancy | No formal contraindications established, since it is still investigational Pregnancy Caution alongside other blood-sugar-lowering medicines | Pregnancy or breastfeeding Any prescription medicine you take regularly, without checking for interactions first Anyone who wants established safety data, because none exists for this compound in humans | Pregnancy or breastfeeding Any prescription medicine you take regularly, without checking for interactions first Anyone who wants established safety data, because none exists for this compound in humans |
What people actually report
Eloralintide
- Stomach side effects.
- Trial-only.
Stop and get help if
- Vomiting badly enough that you cannot keep fluids down
- Signs of an allergic reaction such as face or throat swelling, hives, or trouble breathing
Cagrilintide
- Nausea and other stomach side effects are common.
- It is not approved on its own and is still increased slowly from low doses in trials.
Stop and get help if
- Severe stomach pain that spreads to your back
- Vomiting badly enough that you cannot keep fluids down
Petrelintide
- Stomach side effects.
- Trial-only.
Stop and get help if
- Spreading hives, swelling of the face or throat, or trouble breathing, which can happen with any injection and is a medical emergency
- Redness, heat, or pus at the injection site, which can signal infection
AZD6234
- Stomach side effects.
- Trial-only.
Stop and get help if
- Spreading hives, swelling of the face or throat, or trouble breathing, which can happen with any injection and is a medical emergency
- Redness, heat, or pus at the injection site, which can signal infection
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.